Vemircopan

Vemircopan (ALXN2050) is an orally active complement factor D (FD) inhibitor. Vemircopan can be used in the research of diseases such as myasthenia gravis, lupus nephritis, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria[1][2][3].

Product Specifications

CAS Number

[2086178-00-7]

Product Name Alternative

ALXN2050; ACH 0145228; ACH-5228

UNSPSC

12352005

Target

Complement System; Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vemircopan.html

Purity

98.61

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

C[C@]12[C@](C2)([H])N([C@@H](C1)C(NC3=C(C=CC(Br)=N3)C)=O)C(CN4C5=CC=C(C6=CN=C(C)N=C6)C=C5C(C(C)=O)=N4)=O

Molecular Formula

C29H28BrN7O3

Molecular Weight

602.48

References & Citations

[1]Browett P J, et al. Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: interim data from a phase 2 open-label proof-of-concept study[J]. Blood, 2022, 140 (Supplement 1) : 717-719.|[2]Peixoto VP, et al. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials. Curr Med Res Opin. 2024 May 16:1-11. |[3]Versino F, et al. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. Int J Lab Hematol. 2024 May;46 Suppl 1:43-54.|[4]Prasad RR, et al. An intracellular complement system drives metabolic and proinflammatory reprogramming of vascular fibroblasts in pulmonary hypertension. JCI Insight. 2025 Feb 13;10 (6) :e184141.